In today’s session Pfizer Inc. (PFE) registered an unusually high (1,773) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the June, 2017 call, expecting serious PFE increase. With 1,773 contracts traded and 19014 open interest for the Jun, 17 contract, it seems this is a quite bullish bet. The option with symbol: PFE170616C00035000 closed last at: $1.26 or 16.7% up. The stock increased 0.18% or $0.06 during the last trading session, hitting $33.72. About 20.88M shares traded hands or 10.07% up from the average. Pfizer Inc. (NYSE:PFE) has risen 12.12% since March 1, 2016 and is uptrending. It has outperformed by 2.87% the S&P500.
Analysts await Pfizer Inc. (NYSE:PFE) to report earnings on October, 25. They expect $0.62 EPS, up 3.33% or $0.02 from last year’s $0.6 per share. PFE’s profit will be $3.74B for 13.60 P/E if the $0.62 EPS becomes a reality. After $0.64 actual EPS reported by Pfizer Inc. for the previous quarter, Wall Street now forecasts -3.13% negative EPS growth.
Pfizer Inc. (NYSE:PFE) Ratings Coverage
Out of 18 analysts covering Pfizer (NYSE:PFE), 10 rate it a “Buy”, 0 “Sell”, while 8 “Hold”. This means 56% are positive. $51 is the highest target while $34 is the lowest. The $39.29 average target is 16.52% above today’s ($33.72) stock price. Pfizer has been the topic of 35 analyst reports since July 29, 2015 according to StockzIntelligence Inc. The rating was maintained by Piper Jaffray on Friday, August 14 with “Buy”. The company was maintained on Thursday, April 7 by Jefferies. S&P Research maintained the stock with “Hold” rating in Wednesday, October 28 report. Credit Suisse maintained Pfizer Inc. (NYSE:PFE) on Monday, May 9 with “Outperform” rating. Goldman Sachs maintained Pfizer Inc. (NYSE:PFE) on Monday, April 18 with “Neutral” rating. The firm earned “Outperform” rating on Tuesday, October 20 by Cowen & Co. The firm earned “Overweight” rating on Saturday, September 5 by Piper Jaffray. The rating was maintained by Argus Research with “Buy” on Wednesday, July 29. The firm has “Overweight” rating by JP Morgan given on Thursday, April 7. Argus Research maintained it with “Buy” rating and $46 target price in Tuesday, November 3 report.
Insitutional Activity: The institutional sentiment decreased to 1.03 in Q2 2016. Its down 0.21, from 1.24 in 2016Q1. The ratio worsened, as 80 funds sold all Pfizer Inc. shares owned while 704 reduced positions. 127 funds bought stakes while 678 increased positions. They now own 4.15 billion shares or 5.76% less from 4.40 billion shares in 2016Q1.
Van Hulzen Asset Management Lc last reported 30,929 shares in the company. Investec Asset North America accumulated 0.44% or 84,507 shares. Groesbeck Investment Mgmt Corporation Nj accumulated 0.16% or 6,350 shares. Peregrine Asset Advisers, a Oregon-based fund reported 7,225 shares. Lsv Asset Mgmt holds 35.07M shares or 2.53% of its portfolio. Los Angeles Mgmt And Equity Rech has invested 0.83% of its portfolio in Pfizer Inc. (NYSE:PFE). Greystone Managed Invests holds 0.42% of its portfolio in Pfizer Inc. (NYSE:PFE) for 293,022 shares. Norris Perne And French Limited Liability Partnership Mi last reported 0.1% of its portfolio in the stock. Obermeyer Wood Inv Counsel Lllp last reported 0.02% of its portfolio in the stock. Nicholas Inc Wi has 3.63M shares for 2.58% of their US portfolio. Dynamic Advisors Solutions Limited Co accumulated 6,489 shares or 0.09% of the stock. Cna Financial Corp accumulated 215,491 shares or 1.89% of the stock. Employees Retirement Association Of Colorado has 0.84% invested in the company for 2.87M shares. Products Prns Limited Liability Co holds 203,300 shares or 0.57% of its portfolio. Argentiere Ag holds 35,000 shares or 0.96% of its portfolio.
Insider Transactions: Since May 3, 2016, the stock had 0 insider buys, and 13 sales for $36.04 million net activity. DAMELIO FRANK A also sold $6.46M worth of Pfizer Inc. (NYSE:PFE) on Tuesday, May 10. Another trade for 86,000 shares valued at $2.92M was sold by CANGIALOSI LORETTA V. The insider YOUNG JOHN D sold $1.40 million. LANKLER DOUGLAS M sold $1.00M worth of stock or 29,700 shares. 275,000 shares were sold by READ IAN C, worth $9.30M on Monday, May 9. SUSMAN SALLY also sold $2.29M worth of Pfizer Inc. (NYSE:PFE) shares. Dolsten Mikael also sold $2.26M worth of Pfizer Inc. (NYSE:PFE) shares.
Pfizer Inc. is a research-based global biopharmaceutical company. The company has a market cap of $203.39 billion. The Firm is engaged in discovering, developing and manufacturing of healthcare products. It has a 29.93 P/E ratio. The Company’s divisions include Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.